The surveillance and diagnosis of hepatocellular carcinoma

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 5, 2005, Pages 491-496

  Danta, Mark ^a   Barnes, Eleanor ^a   Dusheiko, Geoffrey ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cirrhosis; Diagnosis; HBV; HCV; Hepatocellular carcinoma; Hepatoma; Screening; Surveillance

Indexed keywords

ALPHA FETOPROTEIN; ANDROGEN; CONTRAST MEDIUM; DECARBOXYPROTHROMBIN; ESTROGEN; GADOLINIUM; INTERLEUKIN 2 RECEPTOR; IRON OXIDE; TRANSFORMING GROWTH FACTOR BETA1;

ARGYROPHILIA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL PRACTICE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COST EFFECTIVENESS ANALYSIS; DYSPLASIA; EUROPE; GENDER; HEALTH PROGRAM; HEALTH SURVEY; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRON OVERLOAD; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER HYPERTROPHY; LIVER RESECTION; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; ULTRASOUND; WILSON DISEASE;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MASS SCREENING; POPULATION SURVEILLANCE; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 17844390681     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200505000-00004     Document Type: Review

References (66)

1. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a Retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463-472.
2. Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnu L, Zoli M, et al. Semi-annual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97:734-744.
3. Calvet X, Bruix J, Bru C, Gines P, Vilana R, Sole M, et al. Natural history of hepatocellular carcinoma in Spain. Five years' experience in 249 cases. J Hepatol 1990; 10:311-317.
4. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26:34S-38S.
5. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-750.
6. Law MG, Roberts SK, Dore GJ, Kaldor JM. Primary hepatocellular carcinoma in Australia, 1978-1997: Increasing incidence and mortality. Med J Aust 2000; 173:403-405.
7. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-1994. Lancet 1997; 350:1142-1143.
8. Deuffic S, Poynard T, Buffa L, Valleron AJ. Trends in primary liver cancer. Lancet 1998; 351:214-215.
9. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19:271-285.
10. Prorok PC. Epidemiologic approach for cancer screening. Problems in design and analysis of trials. Am J Pediatr Hematol Oncol 1992; 14: 117-128.
11. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156.
12. Chalasani N, Said A, Ness R, Hoen H, Lumeng L. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: Results of a national survey. Am J Gastroenterol 1999; 94:2224-2229.
13. Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC, Ye SL, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001; 91:1479-1486.
14. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003; 39:1076-1084.
15. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30:1434-1440.
16. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32:1224-1229.
17. Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111:1018-1022.
18. Nagasue N, Ogawa Y, Yukaya H, Ohta N, Ito A. Serum levels of estrogens and testosterone in cirrhotic men with and without hepatocellular carcinoma. Gastroenterology 1985; 88:768-772.
19. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37:520-527.
20. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-1801.
21. Sakuma K, Saitoh N, Kasai M, Jitsukawa H, Yoshino I, Yamaguchi M, et al. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology 1988; 8:1642-1646.
22. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34:570-575.
23. Lee FI. Cirrhosis and hepatoma in alcoholics. Gut 1966; 7:77-85.
24. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis- associated mortality in the United States from 1979 to 1992: an analysis of multiple-cause mortality data. Ann Intern Med 1998; 129:946-953.
25. Grando-Lemaire V, Guettier C, Chevret S, Beaugrand M, Trinchet JC. Hepatocellular carcinoma without cirrhosis in the West: Epidemiological factors and histopathology of the non-tumorous liver. Groups D'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31: 508-513.
26. Borzio M, Bruno S, Roncalli M, Mels GC, Ramella G, Borzio F, et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology 1995; 108:812-817.
27. Anthony PP, Vogel CL, Barker LF. Liver cell dysplasia: a premalignant condition. J Clin Pathol 1973; 26:217-223.
28. Donato MF, Arosio E, Del Ninno E, Ronchi G, Lampertico P, Morabito A, et al. High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity. Hepatology 2001; 34:523-528.
29. Borzio M, Roncalli M, Trere D, Derenzini M. Preneoplastic cellular changes in liver. Hepatology 1998; 28:1435.
30. Trere D, Borzio M, Morabito A, Borzio F, Roncalli M, Derenzini M. Nucleolar hypertrophy correlates with hepatocellular carcinoma development in cirrhosis due to HBV infection. Hepatology 2003; 37:72-78.
31. Lok AS, Lai CL. Alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989; 9:110-115.
32. Di Bisceglie AM, Hoofnagle JH. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 1989; 64:2117-2120.
33. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepaiology 2002; 36 (5, suppl 1):S84-S92.
34. Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001; 34:603-605.
35. Sheu JC, Sung JL, Chen DS, Lai MY, Wang TH, Yu JY, et al. Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer 1985; 56:660-666.
36. Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003; 226:533-542.
37. Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME, Min AD. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol 2000; 95:1535-1538.
38. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403.
39. Izzo F, Cremona F, Ruffolo F, Palaia R, Parisi V, Curley SA. Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis. Ann Surg 1998; 227:513-518.
40. Sheu JC, Sung JL, Chen DS, Yang PM, Lai MV, Lee CS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985; 89:259-266.
41. Izzo F, Cremona F, Delrio P, Leonardi E, Castello G, Pignata S, et al. Soluble interleukin-2 receptor levels in hepatocellular cancer: a more sensitive marker than alfa fetoprotein. Ann Surg Oncol 1999; 6:178-185.
42. Tsai JF, Jeng JE, Chuang LY, Chang WY, Tsai JH. Urinary transforming growth factor beta1 levels in hepatitis C virus-related chronic liver disease: correlation between high levels and severity of disease. Hepatology 1997; 25:1141-1146.
43. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Bennamou Y, Poynard T, and the MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075.
44. Imbert-Bismut F, Messous D, Thibaut V, Myers RB, Piton A, Thabut D, et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004; 42:323-333.
45. Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, Poynard T. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology 2004; 39:862-863.
46. Blomley MJ, Lim AK, Harvey CJ, Patel N, Eckersley RJ, Basilico R, et al. Liver microbubble transit time compared with histology and Child-Pugh score in diffuse liver disease: a cross sectional study. Gut 2003; 52:1188-1193.
47. Ziol M, Handra-Luca A, Kettaneh A, christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2004; 41:48-54.
48. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430. Summary of the European consensus on the management of HCC.
49. Frazer C. Imaging of hepatocellular carcinoma. J Gastroenterol Hepatol 1999; 14:750-756.
50. Horigome H, Nomura T, Saso K, Itoh M, Joh T, Ohara H. Limitations of imaging diagnosis for small hepatocellular carcinoma: comparison with histological findings. J Gastroenterol Hepatol 1999; 14:559-565.
51. Choi BI, Kim TK, Han JK, Kim AY, Seong CK, Park SJ. Vascularity of hepatocellular carcinoma: assessment with contrast-enhanced second-harmonic versus conventional power Doppler US. Radiology 2000; 214:381-386.
52. Murakami T, Kim T, Takahashi S, Nakamura H. Hepatocellular carcinoma: multidetector row helical CT. Abdom Imaging 2002; 27:139-146.
53. Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38: 1034-1042.
54. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003; 37:1114-1121.
55. 2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004; 64:2418-2423.
56. Miller AB. An epidemiological perspective on cancer screening. Clin Biochem 1995; 28:41-48.
57. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000. Cancer 2004; 100:2415-2421.
58. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance, Gastroenterology 2004; 126:1005-1014. This study demostrates the improved survival with improving management of cirrhosis and HCC.
59. Wong LL, Limm WM, Severino R, Wong LM. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 2000; 6: 320-325.
60. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000; 32(4, pt 1):842-846.
61. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251-259.
62. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31:330-335.
63. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422. Largest randomized controlled trial of screening for HCC.
64. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in Western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101:422-434.
65. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003; 98:679-690.
66. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004; 19:1159-1172.